Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
COSTA MESA, Calif., March 30 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. will hold an investor presentation meeting for shareholders, prospective investors and interested parties in Zurich, Switzerland on April 1, 2009. The purpose of the meeting will be to update the investment community on the company's business.
Company chairman and CEO Chris J. Stern will be available to answer shareholder questions along with the co-chairs of the company's medical advisory board, Dr. Bruce D. Spiess, M.D., FAHA - Professor Anesthesiology and Emergency Medicine, VCURES/ VCU Med Center Richmond, Virginia and Dr. Ross Bullock, M.D. Ph.D.- Professor of Neurosurgery, University of Miami, Miami, Florida.
The three will be in Switzerland in connection with the clinical investigator meeting, a formal initiating step for the Swiss Phase II clinical trial of Oxycyte(R) in traumatic brain injury. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.
The meeting will be webcast live with the webcast available via the investor relations page of the company website.
"This will give European investors a chance to participate in a discussion with management and key researchers," said Stern. "We are also planning a meeting of this type in the U.S. later this year."
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes. More information is available at www.oxybiomed.com.
Minimum Requirements to listen to broadcast:
The Windows Media Player software, downloadable free from
http://www.microsoft.com and at least a 56Kbps connection to the Internet.
If you experience problems listening to the webcast, send an E-mail to: webcast@multivu.com.
CONTACT: Abe Wischnia of Abe Wischnia & Associates, +1-619-795-2345
Web site: http://www.oxybiomed.com/